Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors (Volume II)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 5 May 2025 | Viewed by 2803

Special Issue Editor


E-Mail Website
Guest Editor
Department of Laboratory Medicine, Karolinska Institutet, Division of Clinical Microbiology, ANA Futura, Alfred Nobels Allé 8, Campus Flemingsberg, 14152 Huddinge, Sweden
Interests: solid tumor immunotherapy; TCR; CAR; neoantigens; gene and cell therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Special Issue is a continuation of our previous Special Issue on “Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors” (https://www.mdpi.com/journal/cancers/special_issues/Immunological_Tumors_Receptors).

Immunotherapy for solid tumors represents the current challenge in cancer treatment. The astonishing results achieved in the treatment of leukemia and lymphomas seem hard to obtain for solid cancers, and the reasons for this are not clear. The key factors in developing successful immunotherapy are the choice of antigen to target tumor cells and the immune receptors used to perform the attack. Many strategies using TCRs specific for shared or mutated cancer antigens and different generations of CARs have been developed, but only a few have shown promising results in patients. There is a need for a deeper understanding of the discriminating factors between successful and unsuccessful therapies.

This Special Issue of Cancers on “Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors 2.0”, therefore, encompasses new research articles and timely reviews on the identification and clinical application of immunological receptors targeting mutated antigens expressed by solid tumors.

Dr. Anna Pasetto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • TCR 
  • CAR 
  • solid tumors 
  • mutated antigens 
  • clinical trials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 3057 KiB  
Review
Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer
by Ramya Ayyalasomayajula and Mare Cudic
Cancers 2024, 16(7), 1334; https://doi.org/10.3390/cancers16071334 - 29 Mar 2024
Cited by 1 | Viewed by 2244
Abstract
Siglecs play a key role in mediating cell–cell interactions via the recognition of different sialylated glycoconjugates, including tumor-associated MUC1, which can lead to the activation or inhibition of the immune response. The activation occurs through the signaling of Siglecs with the cytoplasmic immunoreceptor [...] Read more.
Siglecs play a key role in mediating cell–cell interactions via the recognition of different sialylated glycoconjugates, including tumor-associated MUC1, which can lead to the activation or inhibition of the immune response. The activation occurs through the signaling of Siglecs with the cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM)-containing proteins, while the inhibition signal is a result of the interaction of intracellular immunoreceptor tyrosine-based inhibition motif (ITIM)-bearing receptors. The interaction of tumor-associated MUC1 sialylated glycans with Siglecs via ITIM motifs decreases antitumor immunity. Consequently, these interactions are expected to play a key role in tumor evasion. Efforts to modulate the response of immune cells by blocking the immune-suppressive effects of inhibitory Siglecs, driving immune-activating Siglecs, and/or altering the synthesis and expression of the sialic acid glycocalyx are new therapeutic strategies deserving further investigation. We will highlight the role of Siglec’s family receptors in immune evasion through interactions with glycan ligands in their natural context, presented on the protein such as MUC1, factors affecting their fine binding specificities, such as the role of multivalency either at the ligand or receptor side, their spatial organization, and finally the current and future therapeutic interventions targeting the Siglec–sialylated MUC1 immune axis in cancer. Full article
Show Figures

Graphical abstract

Back to TopTop